{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
tubocurarine
to a specific field?
There is one exact (name or code) match for tubocurarine
Status:
US Previously Marketed
Source:
TUBOCURARINE CHLORIDE by HOSPIRA
(1947)
Source URL:
First approved in 1945
Source:
TUBOCURARINE CHLORIDE by BRISTOL MYERS SQUIBB
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Tubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom. Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. Tubocurarine competes with acetylcholine for post-synaptic nicotinic NM receptors and blocks them.
Status:
US Previously Marketed
Source:
TUBOCURARINE CHLORIDE by HOSPIRA
(1947)
Source URL:
First approved in 1945
Source:
TUBOCURARINE CHLORIDE by BRISTOL MYERS SQUIBB
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Tubocurarine, a naturally occurring alkaloid, is used to treat smoking withdrawl syndrom. Tubocurarine, the chief alkaloid in tobacco products, binds stereo-selectively to nicotinic-cholinergic receptors at the autonomic ganglia, in the adrenal medulla, at neuromuscular junctions, and in the brain. Two types of central nervous system effects are believed to be the basis of Tubocurarine's positively reinforcing properties. A stimulating effect is exerted mainly in the cortex via the locus ceruleus and a reward effect is exerted in the limbic system. At low doses the stimulant effects predominate while at high doses the reward effects predominate. Intermittent intravenous administration of Tubocurarine activates neurohormonal pathways, releasing acetylcholine, norepinephrine, dopamine, serotonin, vasopressin, beta-endorphin, growth hormone, and ACTH. Tubocurarine competes with acetylcholine for post-synaptic nicotinic NM receptors and blocks them.
Status:
US Previously Marketed
Source:
METUBINE IODIDE by LILLY
(1949)
Source URL:
First approved in 1949
Source:
METUBINE IODIDE by LILLY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
Status:
Possibly Marketed Outside US
Class (Stereo):
CHEMICAL (ABSOLUTE)
Dimethyltubocurarine (metocurine) is a non-depolarizing muscle relaxant. It binds to muscle acetylcholine receptor by bridging the to alpha and non-alpha subunits from the ligand binding site. Dimethyltubocurarine was used as an anesthesia adjunct to induce skeletal muscle relaxation and to reduce the intensity of muscle contractions in convulsive therapy.
Status:
Possibly Marketed Outside US
Source:
Octaplasma by Octapharma Pharmazeutika Produktionsges M B H [Canada]
Source URL:
First approved in 2013
Source:
BLA125416
Source URL:
Class:
MIXTURE
Status:
US Previously Marketed
Source:
METUBINE IODIDE by LILLY
(1949)
Source URL:
First approved in 1949
Source:
METUBINE IODIDE by LILLY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
Status:
US Previously Marketed
Source:
METUBINE IODIDE by LILLY
(1949)
Source URL:
First approved in 1949
Source:
METUBINE IODIDE by LILLY
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Metocurine, also known as dimethyltubocurarine, is a non-depolarizing muscle relaxant through the neuromuscular blockade. It antagonizes the neurotransmitter action of acetylcholine by binding competitively with cholinergic receptor sites on the motor end-plate. Patients chronically receiving anticonvulsants are relatively resistant to metocurine.
